Foghorn sounds another warning about the class of ‘20
In 2020 76 biotech floats raised a combined $12.7bn. Foghorn is not the first to show that much of the faith was misplaced.
No Ameera glory for Sanofi
Amcenestrant flunks the long-delayed Ameera-3 trial in ER-positive Her2-negative breast cancer, so how much blame can be put on poor study design?
SABCS 2021 – Mutant benefit makes Emerald sparkle
Trial design comes into focus as late-stage readouts loom for Sanofi, Roche and Astrazeneca.
Degrader battle sees Sanofi edged out for now
The French group was to have been first to report key Serd data this year, but has suffered delays as Roche and now Radius beat it to the punch.
The search for a better Faslodex continues
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Biotech’s important upcoming data
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
AACR 2021 preview – the early themes emerge
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
